CRITICALGLP-1 / Weight LossFDA Warning Letter · September 9, 2025

Dr. Gater’s Weight Loss & Wellness

Atlas ID: 2025-09-fda-dr-gater-s-weight-loss-wellness-1p0lw5

FDA issued a warning letter to Dr. Jameelah Gater, MD, of Dr. Gater's Weight Loss & Wellness (Eatonton, GA) in September 2025 after reviewing her website and finding false or misleading claims about compounded semaglutide and tirzepatide products. The website falsely described compounded drugs as 'FDA Approved,' as 'generic' equivalents of brand-name GLP-1 drugs (Ozempic, Wegovy, Mounjaro), and as 'pharmacologically similar' to FDA-approved products, when compounded drugs are not FDA-approved. FDA cited misbranding violations under FDCA sections 502(a) and 502(bb) and warned that failure to correct violations may result in seizure or injunction.

Flagged claims (6)

Semaglutide,[sic] is the generic version of Ozempic/Wegovy. The generic version Semiglutide [sic] allows for affordability and accessibility to everyday consumers looking to attain a healthy weight.

Unsubstantiated efficacy · compounded-as-generic-false-equivalence

Tirzepatide is the active ingredient in Mounjaro….

Other · brand-equivalence-implication

Generic Ozempic

FDA trademark misuse · compounded-as-generic-false-equivalence

FDA Approved

FDA trademark misuse · fda-approved-misuse

Compounded Semiglutide [sic] is the generic equivalent of the brand names and pharmacologically similar to Ozempic & Wegovy.

Comparative claim w/o evidence · compounded-as-generic-false-equivalence

While the Brand Ozempic from retail pharmacies is extremely expensive, Dr. Gater has licensed pharmacies that can dispense Brand Ozempic at a much more affordable price. You can purchase Brand Ozempic through our website at a significant cost savings. All prescription medications including generic Semiglutide [sic] and brand Ozempic require a telemedicine visit with a medical provider prior [sic] a prescription being sent to our partner pharmacies.

Other · brand-drug-sale-misrepresentation

Required actions (3)

You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product).

Claim removal

Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.

Response required · 15 days

Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Injunction

Source

www.fda.gov · FDA Warning Letter

Does your site contain similar claims?

The free site audit scans your whole site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.

Run my free site audit

Worried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.

Check specific copy in the Claim Checker